Climb Bio reports Phase 1 data supporting quarterly CLYM116 dosing

In healthy volunteers, a single 800 mg subcutaneous dose of CLYM116 suppressed free APRIL by more than 90% through 12 weeks and reduced Gd-IgA1 by about 70%. Phase 2 NAVIGATE-2 is enrolling; Phase 3 is expected to start in 2027.